CMRA News and Press, Comera Life Sciences Holdings Inc. From 05/11/23

2023-05-11 11:43:48 ET Comera Life Sciences press release ( NASDAQ: CMRA ): Q1 GAAP EPS of -$0.13. Revenue of $0.39M (-58.9% Y/Y). For further details see: Comera Life Sciences GAAP EPS of -$0.13, revenue of $0.39M

– Significant progress in Comera’s ongoing research collaboration with Regeneron, a leading U.S. biotechnology company – – Further development of Comera’s pipeline candidate CLS-001 (SQ vedolizumab), highlighted by identification of a lead formulatio...

– Notice of Allowance of U.S. patent application received for expansion of core viscosity reduction claims for excipients in SQore ™ platform – – Patent granted in South Korea and Notice of Allowance received for patent application in Japan for ex...

2023-03-16 10:27:20 ET Comera Life Sciences press release ( NASDAQ: CMRA ): Q4 GAAP EPS of -$0.18. Revenue of $0.15M (+114.3% Y/Y). R&D expenses totaled $489 thousand for the three months ended December 31, 2022, compared to $490 thousand for the same period in 2...

– Extended and broadened its ongoing research collaboration with Regeneron, a leading U.S. biotechnology company – – Announced CLS-001 as subcutaneous formulation of vedolizumab, a currently marketed monoclonal antibody for the treatment of inflammatory bowel di...

WOBURN, Mass., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA ) (“Company” or “Comera”), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety and convenie...

WOBURN, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. ( Nasdaq: CMRA ), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient delivery, access, safety and convenience, today announced that the company wil...

WOBURN, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today announced that it has completed a private pla...

WOBURN, Mass., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. ( Nasdaq: CMRA ), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today announced it will be participating in...

Comera Life Sciences press release ( NASDAQ: CMRA ): Q3 GAAP EPS of -$0.20. Revenue of $235M (+167.0% Y/Y). For further details see: Comera Life Sciences GAAP EPS of -$0.20, revenue of $235M